Using targeted probes for imaging and treating breast cancer
Molecularly Targeted Probes for Photodynamic Therapy and Imaging of Breast Cancer
This study is looking at a new way to help people with breast cancer by using special dyes that light up cancer cells during surgery, making it easier for doctors to see and remove them, which could lead to better results and fewer follow-up treatments.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rochester Institute of Technology NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-10358832 on NIH RePORTER |
What this research studies
This research investigates the use of small, peptide-based probes that contain special dyes for imaging and treating breast cancer. The approach combines fluorescence imaging with photodynamic therapy (PDT) to help identify and eliminate cancer cells during surgery. By using a specific targeting agent that binds to a breast cancer biomarker, the treatment aims to improve surgical outcomes and reduce the need for additional operations. Patients may benefit from a less invasive treatment option with fewer side effects compared to traditional therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with breast cancer who are undergoing surgical treatment.
Not a fit: Patients with non-breast cancer conditions or those who are not undergoing surgery for breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for breast cancer patients that minimizes side effects and improves surgical precision.
How similar studies have performed: Other research has shown promise in using targeted imaging and therapy approaches for cancer treatment, indicating potential success for this novel method.
Where this research is happening
Rochester, United States
- Rochester Institute of Technology — Rochester, United States (Active)
Researchers
- Principal investigator: Schmitthenner, Hans F. — Rochester Institute of Technology
- Study coordinator: Schmitthenner, Hans F.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.